2. Search Result
Search Result
Results for "

anti-hyperalgesic

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

4

Peptides

6

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108450
    Polygodial

    Poligodial; Tadeonal

    		 Fungal Infection Inflammation/Immunology
    Polygodial (Poligodial) is an antifungal potentiator . Polygodial is a sesquiterpene with anti-hyperalgesic properties .
    Polygodial
  • HY-106224
    Orexin A (human, rat, mouse)
    Maximum Cited Publications
    6 Publications Verification

    Hypocretin-1 (human, rat, mouse)

    		 Orexin Receptor (OX Receptor) Neurological Disease
    Orexin A (human, rat, mouse) (Hypocretin-1 (human, rat, mouse)), a 33 amino acid excitatory neuropeptide, orchestrates diverse central and peripheral processes. Orexin A (human, rat, mouse) binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) has a role in the regulation of feeding behavior. Orexin A (human, rat, mouse) is an effective anti-nociceptive and anti-hyperalgesic agent in mice and rats .
    Orexin A (human, rat, mouse)
  • HY-106224A
    Orexin A (human, rat, mouse) (TFA)
    Maximum Cited Publications
    6 Publications Verification

    Hypocretin-1 (human, rat, mouse) (TFA)

    		 Orexin Receptor (OX Receptor) Neurological Disease
    Orexin A (human, rat, mouse) (Hypocretin-1 (human, rat, mouse)) TFA, a 33 amino acid excitatory neuropeptide, orchestrates diverse central and peripheral processes. Orexin A (human, rat, mouse) TFA binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) TFA has a role in the regulation of feeding behavior. Orexin A (human, rat, mouse) TFA is an effective anti-nociceptive and anti-hyperalgesic agent in mice and rats .
    Orexin A (human, rat, mouse) (TFA)
  • HY-112437
    PF-06737007

    		Trk Receptor Neurological Disease
    PF-06737007 is a potent pan-Trk inhibitor in cell-based assays with IC50s of 7.7 nM, 15 nM and 3.9 nM for TrkA, TrkB and TrkC, respectively . Anti-hyperalgesic effect .
    PF-06737007
  • HY-112436
    PF-6683324

    Trk-IN-4

    		 Trk Receptor Neurological Disease
    PF-6683324 (Trk-IN-4) is a potent pan-Trk inhibitor in cell-based assays with IC50s of 1.9 nM, 2.6 nM and 1.1 nM for TrkA, TrkB and TrkC, respectively . Anti-hyperalgesic effect .
    PF-6683324
  • HY-N0013
    Vitexin
    5 Publications Verification

    		 Autophagy Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Vitexin is a c-glycosylated flavone, and is found in various medicinal plants species such as Trigonella foenum-graecum Linn. Vitexin has a wide range of pharmacological effects, including anti-oxidant, anti-cancer, anti-inflammatory, anti-hyperalgesic, and neuroprotective effects .
    Vitexin
  • HY-106010
    LBP1

    		Cannabinoid Receptor Neurological Disease
    LBP1 is an orally active and low brain penetrant CB1 receptor agonist. LBP1 exhibits significant anti-allodynic and anti-hyperalgesic effects in rodent models of neuropathic pain .
    LBP1
  • HY-123249
    HZ166

    		GABA Receptor Neurological Disease
    HZ166 is a GABAA receptor subtype-selective benzodiazepine site agonist with preferential activity at α2- and α3-GABAA receptors. HZ166 shows anti-hyperalgesic effects . HZ166 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    HZ166
  • HY-136644
    PD-217014-methyl ester

    		Others Others
    PD-217014-methyl ester is an α?δ ligand with visceral analgesic activity and can inhibit visceral hypersensitivity, and its anti-hyperalgesic effect is dose-dependent.
    PD-217014-methyl ester
  • HY-112434
    PF-06733804

    		Trk Receptor Neurological Disease
    PF-06733804 is a potent pan-Trk inhibitor in cell-based assays with IC50s of 8.4 nM, 6.2 nM and 2.2 nM for TrkA, TrkB and TrkC, respectively . Anti-hyperalgesic effect .
    PF-06733804
  • HY-N7044
    Vitexin arginine

    		Others Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Vitexin arginine is a c-glycosylated flavone, and is found in various medicinal plants species such as Ficus deltoid and Spirodela polyrhiza. Vitexin arginine has a wide range of pharmacological effects, including anti-oxidant, anti-cancer, anti-inflammatory, anti-hyperalgesic, and neuroprotective effects .
    Vitexin arginine
  • HY-N0013R
    Vitexin (Standard)

    		Autophagy Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Vitexin (Standard) is the analytical standard of Vitexin. This product is intended for research and analytical applications. Vitexin is a c-glycosylated flavone, and is found in various medicinal plants species such as Trigonella foenum-graecum Linn. Vitexin has a wide range of pharmacological effects, including anti-oxidant, anti-cancer, anti-inflammatory, anti-hyperalgesic, and neuroprotective effects .
    Vitexin (Standard)
  • HY-P1213A
    JKC363 TFA

    		Melanocortin Receptor Neurological Disease
    JKC363 TFA, a selective melanocortin MC4 receptor antagonist, has a 90-fold higher affinity at the MC4 receptor (IC50=0.5 nM) than at the MC3 receptor (44.9 nM). JKC363 TFA blocks the stimulatory effect of α-MSH on TRH release. Anti-hyperalgesic effect .
    JKC363 TFA
  • HY-P1213
    JKC363

    		Melanocortin Receptor Neurological Disease
    JKC363, a selective melanocortin MC4 receptor antagonist, has a 90-fold higher affinity at the MC4 receptor (IC50=0.5 nM) than at the MC3 receptor (44.9 nM). JKC-363 blocks the stimulatory effect of α-MSH on TRH release. Anti-hyperalgesic effect .
    JKC363
  • HY-19876
    PL37

    Debio-0827

    		 Opioid Receptor Aminopeptidase Neprilysin Neurological Disease Metabolic Disease
    PL37 (Debio-0827) is an orally active Enkephalinase dual inhibitor (dual inhibition refers to the simultaneous inhibition of Neutral Endopeptidase and Aminopeptidase N activities). PL37 exerts its anti-hyperalgesic effects by activating μ-opioid receptors (µ-opioid receptors), with an ED50 value of 13.4 mg/kg for analgesic effects in mice. PL37 can be used to study diabetic neuropathic pain .
    PL37
  • HY-N8117
    Bisabolol oxide A

    		Others Inflammation/Immunology
    Bisabolol oxide A possesses antihyperalgesic and antiedematous effects with oral activity .
    Bisabolol oxide A
  • HY-126941
    Hecogenin acetate

    		Opioid Receptor Neurological Disease
    Hecogenin acetate is a steroidal sapogenin-acetylated with anti-inflammatory and antinociceptive. Hecogenin acetate shows potential antihyperalgesic activity, inhibiting descending pain and acting in opioid receptors .
    Hecogenin acetate
  • HY-112738
    AX048

    		Phospholipase Inflammation/Immunology
    AX048 is an inhibitor for calcium-dependent phospholipase A2 cPLA2 with a XI(50) of 0.022 mole fraction and reveals an antihyperalgesic efficacy .
    AX048
  • HY-107620
    PD 198306

    		MEK Neurological Disease
    PD 198306 is a selective MAPK/ERK-kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects .
    PD 198306
  • HY-130419
    (±)13(14)-EpDPA

    13,14-EpDPE

    		 Others Cardiovascular Disease Neurological Disease
    (±)13(14)-EpDPA (13,14-EpDPE) is the product of the reaction of cytochrome P-450 epoxygenase with Docosahexaenoic Acid (DHA).(±)13(14)-EpDPA has antihyperalgesic and vasorelaxative activities .
    (±)13(14)-EpDPA
  • HY-163733
    AKU-005

    		FAAH MAGL Neurological Disease Inflammation/Immunology
    AKU-005 is a FAAH and MAGL dual inhibitor with IC50 values of 63, 389 nM for rat and human FAAH, respectively. AKU-005 has the potential for the research of trigeminal hyperalgesia .
    AKU-005
  • HY-A0092
    Trimethadione

    3,5,5,-Trimethyloxazolidine-2,4-dione

    		 Calcium Channel Neurological Disease
    Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .
    Trimethadione
  • HY-117474
    MJN110
    2 Publications Verification

    		 MAGL Neurological Disease
    MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively . MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity .
    MJN110
  • HY-15043
    ELN-441958

    		Bradykinin Receptor Inflammation/Immunology Endocrinology
    ELN-441958 is a potent, neutral, competitive and selective bradykinin B1 receptor antagonist with a Ki of 0.26 nM against native human bradykinin B1 receptor. ELN-441958 has high oral bioavailability, and has low CNS exposure in the mouse .
    ELN-441958
  • HY-A0092R
    Trimethadione (Standard)

    		Calcium Channel Neurological Disease
    Trimethadione (Standard) is the analytical standard of Trimethadione. This product is intended for research and analytical applications. Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .
    Trimethadione (Standard)
  • HY-11051
    JNJ-20788560

    		Opioid Receptor Inflammation/Immunology
    JNJ-20788560 is a selective and orally active delta opioid receptor agonist with an affinity of 2.0 nM for DOR (rat brain cortex binding assay). JNJ-20788560 also is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence. JNJ-20788560 can be used for the research of the relief of inflammatory hyperalgesia .
    JNJ-20788560
  • HY-13954
    A 839977
    1 Publications Verification

    		 P2X Receptor Neurological Disease Inflammation/Immunology
    A 839977 is a P2X7 selective antagonist; it blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC50 values are 20 nM, 42 nM and 150 nM respectively) and reduces inflammatory and neuropathic pain in animal models; the antihyperalgesic effects of P2X7 receptor blockade are mediated by blocking the release of IL-1beta .
    A 839977
  • HY-101202A
    (Rac)-SNC80

    (Rac)-NIH 10815

    		 Opioid Receptor Neurological Disease
    (Rac)-SNC80 is a racemate of SNC80 (HY-101202). SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment .
    (Rac)-SNC80
  • HY-121119
    MRS 1523
    3 Publications Verification

    		 Adenosine Receptor Calcium Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology
    MRS 1523 is a potent and selective adenosine A3 receptor antagonist with Ki values of 18.9 nM and 113 nM for human and rat A3 receptors, respectively. In rat this corresponds to selectivities of 140- and 18-fold vs A1 and A2A receptors, respectively. MRS 1523 can exert antihyperalgesic effect through N-type Ca channel block and action potential inhibition in isolated rat dorsal root ganglion (DRG) neurons .
    MRS 1523
  • HY-101202
    SNC80

    NIH 10815

    		 Opioid Receptor Neurological Disease
    SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 also selectively activates μ-δ heteromer in HEK293 cells with an EC50 of 52.8 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment .
    SNC80

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: